Isabel C. P.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase 3 Randomized Double‑Blind Trial of Orelabrutinib Combined with Rituximab and Bendamustine versus Rituximab‑Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma
- A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER
- Efficacy and Safety of Giredestrant vs. Fulvestrant with CDK4/6 Inhibitor in ER+ HER2- Advanced Breast Cancer Resistant to Endocrine Therapy
Data & Insights
Has run more than one trial at 293 of 557 partner sites.
Specializations
Early Breast Cancer Research
The investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative early breast cancer, with particular focus on adjuvant therapeutic approaches. Their research encompasses innovative treatment strategies for localized breast cancer, especially in older patient populations.
- Adjuvant Endocrine Therapy
- CDK4/6 Inhibitor Applications
- Post-operative Treatment Strategies
Advanced Breast Cancer Treatment
Focuses on developing treatments for metastatic breast cancer across multiple subtypes, including HER2-positive and hormone receptor-positive disease. The investigator explores novel therapeutic combinations and targeted approaches for advanced disease stages.
- HER2-Targeted Therapies
- Endocrine Resistance Management
- Novel Drug Combinations
Specialized Therapeutic Areas
Conducts research in specific areas of breast cancer treatment, including brain metastases management and novel therapeutic approaches for resistant disease. Their work includes evaluation of new investigational compounds and targeted therapies.
- Brain Metastases Treatment
- Drug Resistance Mechanisms
- Ophthalmic Safety Studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.